Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Historisch | Analysen |
15.04.2025 15:04:51
|
EQS-News: GeoVax to Present Clinical Data at Upcoming April Industry Events
EQS-News: GeoVax, Inc.
/ Key word(s): Financial
Data to be Presented on the Company’s GEO-CM04S1 and Gedeptin Programs ATLANTA, GA - April 15, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that members of its senior management team and other scientific representatives will participate in two upcoming industry events during April. Event details are as follows:
About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com. Company Contact: Investor Relations Contact: View the original release on www.newmediawire.com News Source: GeoVax, Inc.
15.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
Language: | English |
Company: | GeoVax, Inc. |
United States | |
ISIN: | US3736782000 |
EQS News ID: | 2118468 |
End of News | EQS News Service |
|
2118468 15.04.2025 CET/CEST
Nachrichten zu Geovax Labs Inc
16.04.25 |
EQS-News: GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum (EQS Group) | |
15.04.25 |
EQS-News: GeoVax to Present at the Emerging Growth Conference on April 16, 2025 (EQS Group) | |
15.04.25 |
EQS-News: GeoVax to Present Clinical Data at Upcoming April Industry Events (EQS Group) | |
09.04.25 |
EQS-News: GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent (EQS Group) | |
27.03.25 |
EQS-News: GeoVax Reports 2024 Year-End Financial Results and Provides Business Update (EQS Group) | |
24.03.25 |
EQS-News: GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (EQS Group) | |
12.03.25 |
EQS-News: GeoVax Establishing Strategic Presence in Europe With Initial Footprint in the UK (EQS Group) | |
11.03.25 |
EQS-News: GeoVax to Present at the 37th Annual Roth Conference (EQS Group) |
Dividendenaktien – Wall Street Live mit Tim Schäfer
In der heutigen Ausgabe von Wall Street Live geht es um defensivere Aktien, welche nicht so stark von der Zollpolitik beeinflusst sind. Was sind spannende Aktien und worin ist Tim investiert?
Diese und weitere Fragen beantwortet Tim Schäfer in der heutigen Ausgabe von Wall Street Live.
In unserem zweiwöchigen Format „Wall Street Live“ mit Tim Schäfer behandeln wir Topaktuelle Themen des Marktgeschehens.
🛑 Wichtig: Das Thema Rüstung ist gesellschaftlich wie ethisch komplex – in diesem Video beleuchten wir vor allem die börsentechnische Entwicklung und die wirtschaftlichen Auswirkungen globaler Ereignisse.
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Nach EZB-Entscheid: SMI geht fester ins lange Osterwochenende -- DAX schliesst im MinusDer heimische Aktienmarkt tendierte am Donnerstag fester, während sich der deutsche Aktienmarkt am letzten Handeltag vor Ostern schwächer präsentierte.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |